Omada Health (NASDAQ:OMDA) CFO Steven Cook Sells 17,950 Shares

Omada Health, Inc. (NASDAQ:OMDA) CFO Steven Cook sold 17,950 shares of the company’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $21.07, for a total transaction of $378,206.50. Following the transaction, the chief financial officer owned 115,409 shares in the company, valued at approximately $2,431,667.63. The trade was a 13.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Omada Health Trading Up 1.3%

Shares of NASDAQ OMDA opened at $21.95 on Wednesday. Omada Health, Inc. has a 1 year low of $10.28 and a 1 year high of $26.92. The firm’s 50-day moving average is $16.83 and its 200-day moving average is $14.93. The firm has a market capitalization of $1.30 billion and a PE ratio of -81.30.

Omada Health (NASDAQ:OMDA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03. Omada Health had a negative net margin of 2.22% and a negative return on equity of 1.82%. The business had revenue of $78.05 million during the quarter. As a group, equities research analysts anticipate that Omada Health, Inc. will post -0.01 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Wells Fargo & Company increased their price target on Omada Health from $17.00 to $18.00 and gave the company an “equal weight” rating in a research note on Friday, May 8th. Canaccord Genuity Group set a $24.00 target price on Omada Health in a report on Friday, May 8th. JPMorgan Chase & Co. decreased their target price on Omada Health from $32.00 to $26.00 and set an “overweight” rating for the company in a research report on Thursday, March 12th. Weiss Ratings upgraded shares of Omada Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday. Finally, Barclays lifted their price objective on shares of Omada Health from $18.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Ten analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $22.91.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC bought a new stake in shares of Omada Health in the second quarter worth about $637,000. Walleye Capital LLC bought a new position in shares of Omada Health during the 2nd quarter valued at about $458,000. Ilex Capital Partners UK LLP acquired a new position in shares of Omada Health in the 2nd quarter valued at approximately $201,000. Soros Fund Management LLC acquired a new position in shares of Omada Health in the 2nd quarter valued at approximately $640,000. Finally, Raymond James Financial Inc. bought a new stake in Omada Health during the 2nd quarter worth approximately $32,000.

About Omada Health

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.